Andre Ghetti, Chief Executive Officer
Andre Ghetti, PhD, is CEO of AnaBios. He was formerly the President of AVIVA Biosciences where he led the growth of the company into drug discovery services and intellectual property commercialization. Prior to joining AVIVA Biosciences, Dr. Ghetti was involved in drug discovery programs at Aurora Biosciences, and later at Vertex Pharmaceuticals. Dr. Ghetti received his Ph.D. in Molecular and Cellular Physiology from the University of Verona (Italy) and completed his postdoctoral training at the California Institute of Technology. From 1996 to 2001, Dr. Ghetti worked as a staff scientist at the Salk Institute, in La Jolla, California. During the last several years, he has focused on the creation of new tools and strategies to advance biomedical sciences, with special emphasis on enabling the direct study of human biology and pharmacology to accelerate the rate of successful drug discovery and development.
Paul Miller, Chief Corporate Development Officer
Paul E. Miller, PhD, is a Founding Partner and the Chief Business & Corporate Development Officer of AnaBios. He also founded Consulting Life Sciences, a biotechnology consulting and brokerage firm established in 2007.
Dr. Miller holds a BSc in Biochemistry from Dartmouth College (1979, Hanover, NH, USA) and a PhD in Physiology from McGill University Faculty of Medicine (1989, Montreal, Canada). His scientific career has spanned over 30 years with publications in prestigious journals such as Science and American Journal of Physiology. Over the years, Dr. Miller has conducted research across several areas of human physiology including differentiation and cancer, feto-maternal immunology, protein secretion pathways, intestinal motility and functional genomics.
With an extensive parallel business experience in the cultural artistic industry from 1986 to 2001, Dr. Miller has since combined his scientific expertise and his business acumen for the past 17 years in the biopharmaceutical industry. He has also successfully developed and marketed several innovative projects and services for preclinical CROs aimed at increasing the efficiency of the drug discovery, safety and development processes.
Chris Mathes, Chief Commercial Officer
As Chief Commercial Officer (CCO) of AnaBios, Dr. Chris Mathes provides leadership in business development activities and contributes to the strategic direction of the company. Previously, Mathes acted as the CCO of the early drug discovery company, Icagen. Prior to Icagen, Dr. Mathes led North American business development efforts for Discovery services at Charles River Laboratories. Dr. Mathes was CCO at ChanTest (acquired by Charles River in 2014), a market leader in ion channel drug discovery and associated in vitro safety testing. Prior to ChanTest, he established and managed all aspects of the U.S. subsidiary of Sophion Bioscience A/S (Denmark) as Vice President & General Manager. Mathes has over 25 years of experience in the ion channel field and contributed to the early development and marketing strategy of automated patch clamp systems. He earned a B.S. in Biology from Stanford University (with departmental honors). He received his Ph.D. in Neuroscience from the University of California, Los Angeles in 1995. In 2009, Mathes earned an Executive M.B.A. degree from Rutgers University. He established Candidate Biopharma Advisors in January 2018.
Howard Sampson, Chief Financial Officer
Howard Sampson, CPA, is the CFO of AnaBios. He has over 30 years of financial experience and 25 years in the biotech sphere.
Mr. Sampson was Vice President and Chief Financial Officer for iVOW, Inc. from July 2004 to August 2005, for The Immune Response Corporation from May 1999 to July 2002 and for Genta Inc. from December 1991 to October 1996. At Gen-Probe Inc. from 1985 to 1990, he held various positions including Controller and Treasurer and Chief Financial Accountant, and played an integral role from its inception through its acquisition.
Mr. Sampson has participated in numerous public and private financings, including three IPOs and currently serves as a director on the Board of a privately held company. A Certified Public Accountant (California), he began his career in public accounting at KPMG in San Diego and is a graduate of San Diego State University.
Najah Abi-Gerges, Vice President of Research & Development
Najah Abi-Gerges, PhD, is Vice President of Research & Development at AnaBios. Dr. Abi-Gerges holds a MSc in Physiology and Pharmacology from the University of Poitiers (France) and a PhD in Cardiac Physiology from Paris XI University (France). Prior to joining AnaBios, Dr. Abi-Gerges was involved in drug discovery programs at AstraZeneca plc. With over 17 years in the pharmaceutical industry, he is an innovative leader, having made substantial contributions to drug approvals (like Tagrissoâ a treatment for metastatic EGFR T790M mutation-positive non-small cell lung cancer), research across several areas of cardiac physiology and pharmacology resulting in over 40 published peer-reviewed articles, and novel paradigms to advance cardiovascular translational science. Dr Abi-Gerges is the Editor for the Journal of Pharmacological and Toxicological Methods, and is also a reviewer for more than 20 peer-reviewed scientific journals and review judge panel for various science institutes and foundations. Dr. Abi-Gerges is co-chair of the ion channel group in the CiPA initiative.
Guy Page, Director of Operations
Guy Page, who holds a BSc in biochemistry and an M.Sc. in physiology/biophysics from Sherbrooke University Faculty of Medicine (Quebec, Canada), is the Director of Operations at AnaBios. He has more than 18 years of scientific experience, including 16 years performing contract research for the pharmaceutical industry. After serving as the study director for IPS Therapeutique for four years, Page came to San Diego to initiate the GLP-compliant human cardiac testing platform at AVIVA Biosciences. Since AnaBios’ inception, he has become instrumental in solidifying the company’s foundations. He’s also focused on directing in-vitro electrophysiology techniques related to human cardiovascular pharmacology safety and toxicology, as well as assessing pain outcomes on human dorsal root ganglions for the biopharmaceutical industry.